Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20364406 | 0.87 | TAS2R8 (0.53) | TAS2R8DRD4RIPK1 | |
| SCHEMBL20162181 | 0.85 | KDM4C (0.47) | KDM4CTAS2R8DRD4CYP3A4CYP2C9 | |
| SCHEMBL20367354 | 0.84 | TAS2R8 (0.47) | KDM4CTAS2R8DRD4CYP3A4CYP2C9 | |
| SCHEMBL20162177 | 0.84 | KDM4C (0.46) | KDM4CTAS2R8DRD4CYP3A4CYP2C9 | |
| SCHEMBL20367225 | 0.84 | KDM4C (0.48) | KDM4CTAS2R8DRD4CYP3A4CYP2C9 | |
| SCHEMBL20162109 | 0.83 | TAS2R8 (0.49) | KDM4CTAS2R8KCNH2 | |
| SCHEMBL20367488 | 0.83 | KDM4C (0.47) | KDM4CTAS2R8CYP3A4CYP2C9KCNH2 | |
| SCHEMBL20330427 | 0.82 | KDM4C (0.46) | KDM4CTAS2R8CYP3A4CYP2C9 | |
| SCHEMBL20367121 | 0.81 | ABCB1 (0.44) | KDM4CTAS2R8ACKR3 | |
| SCHEMBL20162168 | 0.81 | TAS2R8 (0.44) | KDM4CTAS2R8DRD4CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | NR0B1, NR2E1, NR0B2 | KDM4C 1041/4885TAS2R8 2479/4885DRD4 2382/4885 |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | KDM4C 1041/4885TAS2R8 2479/4885DRD4 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.